{
    "clinical_study": {
        "@rank": "119303", 
        "arm_group": [
            {
                "arm_group_label": "E1. CG400549 640mg", 
                "arm_group_type": "Experimental", 
                "description": "CG400549 640mg BID on Day 1-5 and QD on Day 6 in the fed-state"
            }, 
            {
                "arm_group_label": "E2: CG400549 320mg", 
                "arm_group_type": "Experimental", 
                "description": "CG400549 320mg QD on Day 1-5 in the fed-state."
            }, 
            {
                "arm_group_label": "E3: CG400549 640mg", 
                "arm_group_type": "Experimental", 
                "description": "CG400549 640mg QD on Day 1-5 in the fed-state."
            }, 
            {
                "arm_group_label": "E4: CG400549 960mg", 
                "arm_group_type": "Experimental", 
                "description": "CG400549 960mg QD on Day 1-5 in the fed-state."
            }, 
            {
                "arm_group_label": "P1 Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 640mg BID on Day 1-5 and QD on Day 6 in the fed-state"
            }, 
            {
                "arm_group_label": "P2: Placebo 320mg", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 320mg QD on Day 1-5 in the fed-state"
            }, 
            {
                "arm_group_label": "P3 Placebo 640mg", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 640mg QD on Day 1-5 in the fed-state."
            }, 
            {
                "arm_group_label": "P4: Placebo 960mg", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 960mg QD on Day 1-5 in the fed-state."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety and tolerability of 3 multiple and\n      escalating dose regimens of CG400549 administered orally in healthy volunteers."
        }, 
        "brief_title": "Multiple Ascending Doses Study of CG400549", 
        "completion_date": {
            "#text": "March 2011", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This is a Phase 1, 3 cohorts study consisting of a randomised, double-blind, and\n      placebo-controlled design."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age:18-55 years, inclusive\n\n          -  Body Mass Index :19-30 kg/m2, inclusive\n\n          -  Sex:male\n\n          -  Other criteria:healthy; non-smoking or smoking \u2264 10 cigarettes/day\n\n        Exclusion Criteria:\n\n          -  Evidence of clinically relevant pathology\n\n          -  History of bacterial or viral infection requiring treatment with   antibiotics or\n             antivirals within 1 month of study\n\n          -  Presence or history of esophageal or gastroduodenal ulceration within 1 month before\n             screening."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01848470", 
            "org_study_id": "CG400549-1-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "E1. CG400549 640mg", 
                "description": "multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state", 
                "intervention_name": "CG400549 640mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "E2: CG400549 320mg", 
                "description": "multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state", 
                "intervention_name": "CG400549 320 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "E3: CG400549 640mg", 
                "description": "multiple oral doses of 640 mg CG400549 (n=6) QD for 5 days in the fed state", 
                "intervention_name": "CG400549 640 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "E4: CG400549 960mg", 
                "description": "multiple oral doses of 960 mg CG400549 (n=6) QD for 5 days in the fed state", 
                "intervention_name": "CG400549 960 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "P1 Placebo", 
                "description": "multiple oral doses of 640 mg placebo (n=2) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state", 
                "intervention_name": "Placebo 640mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "P2: Placebo 320mg", 
                "description": "multiple oral doses of 320 mg placebo (n=2) QD for 5 days in the fed state", 
                "intervention_name": "Placebo 320mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "P3 Placebo 640mg", 
                "description": "multiple oral doses of 960 mg placebo (n=2) QD for 5 days in the fed state", 
                "intervention_name": "placebo 960 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "P4: Placebo 960mg", 
                "description": "multiple oral doses of 640 mg placebo (n=2) QD for 5 days in the fed state", 
                "intervention_name": "Placebo 640mg", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 3, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zuidlaren", 
                    "country": "Netherlands"
                }, 
                "name": "PRA International clinical center"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "8", 
        "official_title": "Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of Multiple Ascending Doses of CG400549 in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "CrystalGenomics, Inc.", 
            "last_name": "Seonggu Ro, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "From Time the ICF is signed until Follow up Visit (15 days after study drug administration)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01848470"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To determine the pharmacokinetics of CG400549 following oral administration of multiple  ascending doses of CG400549 in healthy male subjects.", 
            "measure": "Pharmacokinetics-tmax(h), Cmax (ng/mL), Auc (0-24), T1/2(h)", 
            "safety_issue": "No", 
            "time_frame": "Day1 and Day5"
        }, 
        "source": "CrystalGenomics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CrystalGenomics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}